ZALDARIDE MALEATE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C26H28N4O2.C4H4O4
Molecular Weight	544.5983
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C/C(O)=O.CC4(CN1CCC(CC1)N2C(=O)NC3=C2C=CC=C3)OCC5=CC=CC=C5N6C=CC=C46

InChI

InChIKey=NGODOSILXOFQPH-BTJKTKAUSA-N

InChI=1S/C26H28N4O2.C4H4O4/c1-26(24-11-6-14-29(24)22-9-4-2-7-19(22)17-32-26)18-28-15-12-20(13-16-28)30-23-10-5-3-8-21(23)27-25(30)31;5-3(6)1-2-4(7)8/h2-11,14,20H,12-13,15-18H2,1H3,(H,27,31);1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula	C26H28N4O2
Molecular Weight	428.5261
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1379190 | https://www.ncbi.nlm.nih.gov/pubmed/8562742 | https://www.ncbi.nlm.nih.gov/pubmed/3033469 |

Zaldaride is a calmodulin antagonist known to produce inhibition of calmodulin-dependent voltage-gated ion channels including those of Ca2 , Na , and K . Zaldaride was also observed to inhibit nicotinic acetylcholine receptor (nAChR) channel currents. Zaldaride has been studied in clinical trials as a potential treatment for travelers diarrhea.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C 3 Target ID: Q14123 Gene ID: 5137.0 Gene Symbol: PDE1C Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/3033469	Inhibitor 8504		3.3 µM [IC50]
Voltage-gated potassium channel 17 Target ID: CHEMBL2362996 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25796172	Inhibitor 8504		0.81 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Travelers’ diarrhea 7 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8562742	Curative		Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
378 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
1650 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED
15039 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED
6349 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED
9522 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED
30421 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED
7763 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	10 mg/kg single, subcutaneous dose: 10 mg/kg route of administration: Subcutaneous experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED
18030 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	30 mg/kg single, subcutaneous dose: 30 mg/kg route of administration: Subcutaneous experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
90 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED
90 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED
35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED
35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED
60 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	10 mg/kg single, subcutaneous dose: 10 mg/kg route of administration: Subcutaneous experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED
60 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10784416/	30 mg/kg single, subcutaneous dose: 30 mg/kg route of administration: Subcutaneous experiment type: SINGLE co-administered:	ZALDARIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
20 mg 4 times / day steady, oral Highest studied dose\|Studied dose Dose: 20 mg, 4 times / day Route: oral Route: steady Dose: 20 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8440431/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8440431/	Sources: https://pubmed.ncbi.nlm.nih.gov/8440431/
20 mg 4 times / day steady, oral Studied dose Dose: 20 mg, 4 times / day Route: oral Route: steady Dose: 20 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8562742/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8562742/	Sources: https://pubmed.ncbi.nlm.nih.gov/8562742/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP19A1 429 CYP1A2 2153 CYP2C19 2057	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65909#section=Biological-Test-Results Page: 31.0	inconclusive [IC50 29.8493 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65909#section=Biological-Test-Results Page: 33.0	inconclusive [IC50 30.9008 uM]
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65909#section=Biological-Test-Results Page: 114.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65909#section=Biological-Test-Results Page: 2.0	yes [IC50 1.3803 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65909#section=Biological-Test-Results Page: 2.0	yes [IC50 1.7377 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65909#section=Biological-Test-Results Page: 17.0	yes [IC50 21.8761 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65909#section=Biological-Test-Results Page: 5.0	yes [IC50 9.7717 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65909#section=Biological-Test-Results Page: 5 \| 114	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65909#section=Biological-Test-Results Page: 5.0

PubMed

Title	Date	PubMed
The calmodulin inhibitor CGS 9343B inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells.	2015-06-15	25796172
Zaldaride maleate (a new calmodulin antagonist) versus loperamide in the treatment of traveler's diarrhea: randomized, placebo-controlled trial.	1995-08	8562742
CGS 9343B, a novel, potent, and selective inhibitor of calmodulin activity.	1987-05	3033469

Patents

Sample Use Guides

In Vivo Use Guide

Treatment of traveler's diarrhea: 20 mg zaldaride maleate four times per day

Route of Administration: Oral

In Vitro Use Guide

Zaldaride (CGS 9343B) inhibited Kv currents in rabbit coronary arterial smooth muscle cells in a concentration-dependent manner, with a half-maximal inhibitory concentration (IC50) value of 0.81uM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:41 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:41 GMT 2025`
Record UNII	K7SG01P7NJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZALDARIDE MALEATE

Common Name

English

KW-5617

Preferred Name

English

ZALDARIDE MALEATE [MI]

Common Name

English

ZALDARIDE MALEATE [MART.]

Common Name

English

1,3-DIHYDRO-1-(1-((4-METHYL-4H,6H-PYRROLO(1,2-A)(4,1)BENZOXAZEPIN-4-YL)METHYL)-4-PIPERIDINYL)-2H-BENZIMIDAZOL-2-ONE MALEATE

Systematic Name

English

CGS-9434B

Code

English

(±)-1-(1-((4-METHYL-4H,6H-PYRROLO(1,2-A)(4,1)BENZOXAZEPIN-4-YL)METHYL)-4-PIPERIDYL)-2-BENZIMIDAZOLINONE MALEATE

Systematic Name

English

ZY-17617B

Code

English

Code System Code Type Description

FDA UNII

K7SG01P7NJ

Created by admin on Mon Mar 31 18:07:41 GMT 2025 , Edited by admin on Mon Mar 31 18:07:41 GMT 2025

PRIMARY

CAS

109826-27-9

Created by admin on Mon Mar 31 18:07:41 GMT 2025 , Edited by admin on Mon Mar 31 18:07:41 GMT 2025

PRIMARY

PUBCHEM

6450522

Created by admin on Mon Mar 31 18:07:41 GMT 2025 , Edited by admin on Mon Mar 31 18:07:41 GMT 2025

PRIMARY

MERCK INDEX

m11578

Created by admin on Mon Mar 31 18:07:41 GMT 2025 , Edited by admin on Mon Mar 31 18:07:41 GMT 2025

PRIMARY

Merck Index

Related Record Type Details


					GH66PET6S3

ZALDARIDE

PARENT -> SALT/SOLVATE


					91XW058U2C

Maleic Acid

PARENT -> SALT/SOLVATE

Related Record Type Details


					GH66PET6S3

ZALDARIDE

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1379190 | https://www.ncbi.nlm.nih.gov/pubmed/8562742 | https://www.ncbi.nlm.nih.gov/pubmed/3033469 |

Originator

Approval Year

Targets

Conditions

Approved Use

Cmax

AUC

T1/2

Doses

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1379190 | https://www.ncbi.nlm.nih.gov/pubmed/8562742 | https://www.ncbi.nlm.nih.gov/pubmed/3033469 |

C_max

T_1/2

Drug as perpetrator